← Back to all trials
Recruiting
NCT07896941
Safety and Efficacy of CG-BM1 in Ischemic Stroke
Conditions: Ischemic Stroke or High-risk TIA (ABCD² ≥ 4)
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE1, PHASE2
Enrollment: 87
Sponsor: GuangZhou Cellgenes Biotechnology Co., Ltd.
Location: The First Affiliated Hospital, Sun Yat-sen University Guangzhou
Summary
1. To evaluate the safety and tolerability of CG-BM1 for the treatment of patients with Ischemic Stroke.
2. To observe the preliminary effectiveness of CG-BM1 in treating Ischemic Stroke patients.
Eligibility Criteria
Inclusion Criteria:
* Age ≥18 years; male or female.
* 3 to 60 months after onset of ischemic stroke.
* Screening imaging shows ischemic stroke consistent with anterior circulation infarction, with no new infarct lesions.
* Currently receiving standard medical therapy for secondary prevention of stroke.
* Modified Rankin Scale (mRS) score 3-4.
* National Institutes of Health Stroke Scale (NIHSS) score 6-20, with item 1a \8.5%); renal disease (eGFR \
Source: ClinicalTrials.gov (NCT07896941). StuddyBuddy aggregates publicly available trial information.
